利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

70 records (took 0.034 seconds)

    STREM1 MARKER PANELS FOR EARLY DETECTION OF SEPSIS
    2.
    发明公开
    STREM1 MARKER PANELS FOR EARLY DETECTION OF SEPSIS 审中-公开

    公开(公告)号：US20240230674A1

    公开(公告)日：2024-07-11

    申请号：US18558119

    申请日：2022-04-29

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Felix Gruenewald ,  Victor Johann Raul Jeger ,  Martin Klammer ,  Philipp Schuetz ,  Maria von Holtey ,  Stephen Weber ,  Heike Wegmeyer ,  Ursula-Henrike Wienhues-Thelen

    IPC: G01N33/68 ,  G16H50/20

    CPC classification number: G01N33/6893 ,  G16H50/20 ,  G01N2800/26

    Abstract: The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being STREM1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: Aspartate aminotransferase, Bilirubin, ESM-1, HBP (Heparin-binding protein), a cardiac Troponin, Alanine aminotransferase, and IL6, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being STREM1 and a second biomarker selected from the group consisting of: Aspartate aminotransferase, Bilirubin, ESM-1, HBP (Heparin-binding protein), a cardiac Troponin, Alanine aminotransferase, and IL6 or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.

    IGFBP7 MARKER PANELS FOR EARLY DETECTION OF SEPSIS
    3.
    发明公开
    IGFBP7 MARKER PANELS FOR EARLY DETECTION OF SEPSIS 审中-公开

    公开(公告)号：US20240219404A1

    公开(公告)日：2024-07-04

    申请号：US18557954

    申请日：2022-04-29

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Felix Gruenewald ,  Victor Johann Raul Jeger ,  Martin Klammer ,  Philipp Schuetz ,  Maria von Holtey ,  Stephen Weber ,  Heike Wegmeyer ,  Ursula-Henrike Wienhues-Thelen

    IPC: G01N33/68 ,  G16H50/20

    CPC classification number: G01N33/6893 ,  G16H50/20 ,  G01N2333/91188 ,  G01N2800/26 ,  G01N2800/50

    Abstract: The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being IGFBP7, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being IGFBP7 and a second biomarker selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.

    Marker for statin treatment stratification in heart failure
    5.
    发明授权
    Marker for statin treatment stratification in heart failure 有权

    公开(公告)号：US11460474B2

    公开(公告)日：2022-10-04

    申请号：US16257770

    申请日：2019-01-25

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Hanspeter Brunner ,  Thomas Dieterle ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC: G01N33/543 ,  G01N33/68 ,  A61K31/40 ,  G01N33/62

    Abstract: The present disclosure is directed to a method of identifying a patient having heart failure as likely to respond to a therapy with a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein the patient has heart failure and undergoes a therapy with a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

Patent Agency Ranking